iPSC-derived CD19 CAR NK cells for relapsed or refractory lymphoma

被引：0
|
作者：
Shapiro, Roman M. [1 ]
Romee, Rizwan [1 ]
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, Div Transplantat & Cellular Therapies, Boston, MA 02215 USA
来源：
LANCET | 2025年 / 405卷 / 10473期
关键词：
D O I：
10.1016/S0140-6736(24)02524-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：98 / 99
页数：2
相关论文
共 50 条
  • [21] CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells
    Wang, Linqin
    Wang, Yiyun
    He, Xiangjun
    Mo, Zhuomao
    Zhao, Mengyu
    Liang, Xinghua
    Hu, Kejia
    Wang, Kexin
    Yue, Yanan
    Mo, Guolong
    Zhou, Yixuan
    Hong, Ruimin
    Zhou, Linghui
    Feng, Youqin
    Chen, Nian
    Shen, Lihong
    Song, Xiaobin
    Zeng, Wenxiu
    Jia, Xiaofeng
    Shao, Yuxuan
    Zhang, Peng
    Xu, Mengqi
    Wang, Dongrui
    Hu, Yongxian
    Yang, Luhan
    Huang, He
    CELL REPORTS MEDICINE, 2025, 6 (01)
  • [22] Engineered iPSC-Derived NK Cells Expressing Recombinant CD64 for Enhanced ADCC
    Dixon, Kate
    Hullsiek, Robert
    Snyder, Kristin
    Davis, Zachary
    Khaw, Melissa
    Lee, Tom
    Chu, Hui-Yi
    Abujarour, Ramzey
    Dinella, Jason
    Rogers, Paul
    Bjordahl, Ryan
    Miller, Jeffrey S.
    Valamehr, Bahram
    Wu, Jianming
    Walcheck, Bruce
    BLOOD, 2020, 136
  • [23] CD19 Redirected CAR NK Cells Are Equally Effective but Less Toxic Than CAR T Cells
    Quintarelli, Concetta
    Sivori, Simona
    Caruso, Simona
    Carlomagno, Simona
    Boffa, Iolanda
    Orlando, Domenico
    Guercio, Marika
    Cembrola, Biancamaria
    Pitisci, Angela
    Di Cecca, Stefano
    Li Pira, Giuseppina
    Vinti, Luciana
    De Angelis, Biagio
    Moretta, Lorenzo
    Locatelli, Franco
    BLOOD, 2018, 132
  • [24] Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed/ refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expression
    Danylesko, Ivetta
    Shem-Tov, Noga
    Yerushalmi, Ronit
    Jacoby, Elad
    Toren, Amos
    Shouval, Roni
    Itzhaki, Orit
    Avigdor, Abraham
    Shimoni, Avichai
    Nagler, Arnon
    CURRENT RESEARCH IN TRANSLATIONAL MEDICINE, 2024, 72 (04)
  • [25] CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results
    Jae H. Park
    Karthik Nath
    Sean M. Devlin
    Craig S. Sauter
    M. Lia Palomba
    Gunjan Shah
    Parastoo Dahi
    Richard J. Lin
    Michael Scordo
    Miguel-Angel Perales
    Roni Shouval
    Ana Alarcon Tomas
    Elizabeth Cathcart
    Elena Mead
    Bianca Santomasso
    Andrei Holodny
    Renier J. Brentjens
    Isabelle Riviere
    Michel Sadelain
    Nature Medicine, 2023, 29 : 1710 - 1717
  • [26] CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?
    Kinoshita, Hannah
    Bollard, Catherine M.
    Toner, Keri
    SEMINARS IN HEMATOLOGY, 2023, 60 (05) : 329 - 337
  • [27] CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results
    Park, Jae H.
    Nath, Karthik
    Devlin, Sean M.
    Sauter, Craig S.
    Palomba, M. Lia
    Shah, Gunjan
    Dahi, Parastoo
    Lin, Richard J. J.
    Scordo, Michael
    Perales, Miguel-Angel
    Shouval, Roni
    Tomas, Ana Alarcon
    Cathcart, Elizabeth
    Mead, Elena
    Santomasso, Bianca
    Holodny, Andrei
    Brentjens, Renier J.
    Riviere, Isabelle
    Sadelain, Michel
    NATURE MEDICINE, 2023, 29 (07) : 1710 - +
  • [28] Multiple Doses of Cnty-101, an iPSC-Derived Allogeneic CD19 Targeting CAR-NK Product, Are Safe and Result in Tumor Microenvironment Changes Associated with Response: A Case Study
    Ramachandran, Indu
    Rothman, Sarah
    Clausi, Mariano
    Mcfadden, Kile
    Salantes, Brenda
    Jih, Gloria
    Brigman, Thomas
    Kelly, Sam
    Hall, Matthew S.
    Yee, Stephanie
    Koumenis, Iphigenia
    Das, Poulomee
    Briggs, Jordan
    Braun, Tori
    Yuan, Ying
    Devlin, Elizabeth
    Farid, Adrienne
    Trede, Nikolaus S.
    Moyo, Tamara K.
    Latif, Tahir
    Patel, Krish
    BLOOD, 2023, 142
  • [29] Safety and efficacy of optimized tandem CD19/CD20 CAR-engineered T cells in patients with relapsed/refractory non-Hodgkin lymphoma.
    Zhang, Yajing
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma
    Eugenio Galli
    Federica Sorà
    Stefan Hohaus
    Silvia Bellesi
    Francesco Autore
    Elisabetta Metafuni
    Idanna Innocenti
    John Marra
    Alberto Fresa
    Maria Assunta Limongiello
    Sabrina Giammarco
    Lucia Leccisotti
    Andrea Guarneri
    Patrizia Chiusolo
    Luca Laurenti
    Luciana Teofili
    Nicola Piccirillo
    Andrea Bacigalupo
    Simona Sica
    Bone Marrow Transplantation, 2022, 57 : 837 - 839
12345